Swissmedic
REGULATORY UPDATE
Revision of the Guidance document Authorisation Biosimilar
Published: 10/1/2026Detected: 10/1/2026
Summary preview
Revision of the Swissmedic guidance for authorisation of biosimilars may refine the regulatory expectations for demonstrating biosimilarity, including how applicants structure supporting evidence.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountimmunology
manufacturing
quality
clinical
safety
labeling
#biosimilar
#Swissmedic
#authorisation
#biosimilarity
#comparability exercise
Official Source Document Source Verified
Access the original document directly from SWISSMEDIC.
More from Swissmedic
- Extended deadline for publishing officially mandated information materials on the electronic publication platform11/12/2026
- Designer drugs: FDHA brings further psychoactive substances under control11/10/2026
- NAD+ supplements: When lifestyle products have criminal consequences11/9/2026
- Publication eCTD v4.0 Implementation Guide Package v2.011/9/2026
- Save the Date: Clinical Trials Symposium 202711/4/2026